Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	SPL
Latest Price:	1.35 (-0.37% )
52-week High:	1.66
52-week Low:	0.96
Market Cap:	333.60M

1 year chart

1 day chart

Starpharma Holdings

Starpharma Holdings (ASX: SPL) is focused on the development of dendrimer nanotechnology for pharmaceutical, drug delivery and other applications. Products based on Starpharma’s dendrimer technology are already on the market as diagnostic elements and laboratory reagents through licence agreements.

Starpharma Holdings finishes quarter with $24m cash position

Tuesday, April 27, 2010

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) has released its quarterly report for the period ended 31 March 2010.

The cash position at 31 March 2010 was $23.7m compared to the 31 December 2009 total of $24.3m.

Operating & investing cash outflow was $0.6m for the quarter. Receipts from customers included royalty and license income from partners including SSL International, Siemens Healthcare and Elanco, and grant payments from the U.S. National Institutes of Health (NIH) for VivaGel® development costs.

Operational highlights announced during the quarter included:

- the successful completion of a VivaGel® study in sexually active women; and
- signing of a new drug delivery collaboration with Eli Lilly and Company in human pharmaceuticals.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.